

ASX Release

Oventus investor information sessions

Brisbane, Australia 30 April 2019: Oventus Medical Ltd (ASX: OVN) is pleased to invite investors to attend a series of information sessions being held across Brisbane, Sydney and Melbourne in May. During the events, CEO, Dr Chris Hart will discuss Oventus' progress in rolling out its Sleep Treatment Platform across key markets.

The following sessions are available to those investors able to attend:

Brisbane	Wednesday, 8 May 2019 12.15pm arrival for a 12.30pm start – a sandwich lunch will be provided Thomson Geer - Boardroom, Level 16, Waterfront Place, 1 Eagle Street, Brisbane
Sydney	Monday, 13 May 2019 5.45pm arrival for a 6.00pm start Thomson Geer - Boardroom, Level 25, 1 O'Connell Street, Sydney
Melbourne	Tuesday, 14 May 2019 5.45pm arrival for a 6.00pm start Thomson Geer - Boardroom, Level 39, Rialto South Tower, 525 Collins Street, Melbourne

Please RSVP to attend

Investors wishing to register interest in attending one of the above events, can do so by emailing phillipa@oventus.com.au or phoning Phillipa Thorn on +61 0427 783 994 with briefing session of interest, number of people attending and any dietary requirements.

The Oventus team looks forward to seeing those investors that are able to attend.

—ENDS—

Oventus invites you to follow our progress via our website at www.o2vent.com.

For more information, please contact:

Dr Chris Hart, Managing Director and CEO: M: +61 409 647 496

Jane Lowe, IR Department: M: +61 411 117 774 or jane.lowe@irdepartment.com.au

About Oventus

Oventus is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while maintaining a stable airway with or without nasal CPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O₂Vent® is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.³

¹ Deloitte Access Economics. *Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² Beecroft, et al. *Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

³ Sutherland et al. *Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*